Literature DB >> 31257208

The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293).

Ahmet Emre Eskazan1, Teoman Soysal2.   

Abstract

Entities:  

Year:  2019        PMID： 31257208      PMCID： PMC6601083          DOI： 10.3324/haematol.2019.222000

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.

Authors:  Ahmet Emre Eskazan; Tugrul Elverdi; Fevzi Firat Yalniz; Ayse Salihoglu; Muhlis Cem Ar; Seniz Ongoren Aydin; Zafer Baslar; Yildiz Aydin; Nukhet Tuzuner; Ugur Ozbek; Teoman Soysal
Journal:  Leuk Lymphoma       Date:  2014-05-06

2.  Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Authors:  Adi J Klil-Drori; Hui Yin; Laurent Azoulay; Michaël Harnois; Michel-Olivier Gratton; Lambert Busque; Sarit E Assouline
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

3.  The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?

Authors:  Ahmet Emre Eskazan; Muhlis Cem Ar; Teoman Soysal
Journal:  Leuk Lymphoma       Date:  2014-08-20

4.  First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.

Authors:  Ahmet Emre Eskazan; Mesut Ayer; Bulent Kantarcioglu; Deniz Arica; Naciye Demirel; Demet Aydin; Fevzi Firat Yalniz; Tugrul Elverdi; Ayse Salihoglu; Muhlis Cem Ar; Seniz Ongoren Aydin; Zafer Baslar; Yildiz Aydin; Nukhet Tuzuner; Ugur Ozbek; Teoman Soysal
Journal:  Br J Haematol       Date:  2014-05-10       Impact factor: 6.998

5.  Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.

Authors:  Teoman Soysal; Ahmet Emre Eskazan; Muhlis Cem Ar
Journal:  Expert Rev Hematol       Date:  2014-10-08       Impact factor: 2.929

6.  Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.

Authors:  Ahmet Emre Eskazan; Sevil Sadri; Dilek Keskin; Mesut Ayer; Bulent Kantarcioglu; Naciye Demirel; Demet Aydin; Fuat Aydinli; Osman Yokus; Isil Erdogan Ozunal; Selin Berk; Fevzi Firat Yalniz; Tugrul Elverdi; Ayse Salihoglu; Muhlis Cem Ar; Seniz Ongoren; Zafer Baslar; Yildiz Aydin; Nukhet Tuzuner; Ugur Ozbek; Teoman Soysal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-08-04
  6 in total
  1 in total

1.  Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients

Authors:  Sinan Mersin; Ayfer Gedük; Özgür Mehtap; Pınar Tarkun; Serkan Ünal; Merve Gökçen Polat; Kemal Aygün; Emel Merve Yenihayat; Hayrunnisa Albayrak; Abdullah Hacıhanifioğlu
Journal:  Turk J Haematol       Date:  2021-05-05       Impact factor: 1.831
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.